Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Leishmania major | polypeptide deformylase-like protein, putative | 0.0267 | 0.3558 | 0.5 |
Plasmodium falciparum | peptide deformylase | 0.0701 | 1 | 1 |
Toxoplasma gondii | PLU-1 family protein | 0.0048 | 0.0299 | 0.0299 |
Schistosoma mansoni | jumonji/arid domain-containing protein | 0.0087 | 0.0874 | 0.5 |
Treponema pallidum | polypeptide deformylase (def) | 0.0701 | 1 | 0.5 |
Wolbachia endosymbiont of Brugia malayi | peptide deformylase | 0.0701 | 1 | 0.5 |
Toxoplasma gondii | hypothetical protein | 0.0701 | 1 | 1 |
Brugia malayi | jmjC domain containing protein | 0.0135 | 0.159 | 0.5 |
Echinococcus multilocularis | Jumonji, AT rich interactive domain 1B | 0.011 | 0.1217 | 1 |
Toxoplasma gondii | histone lysine demethylase JMJC1/KDM5D/JARID1D | 0.0035 | 0.0111 | 0.0111 |
Trypanosoma brucei | Polypeptide deformylase 1 | 0.0267 | 0.3558 | 0.5 |
Trypanosoma cruzi | Peptide deformylase 2, putative | 0.0267 | 0.3558 | 0.5 |
Trypanosoma cruzi | polypeptide deformylase-like protein, putative | 0.0267 | 0.3558 | 0.5 |
Trypanosoma cruzi | Peptide deformylase 2, putative | 0.0267 | 0.3558 | 0.5 |
Trypanosoma cruzi | polypeptide deformylase-like protein, putative | 0.0267 | 0.3558 | 0.5 |
Trypanosoma brucei | Peptide deformylase 2 | 0.0267 | 0.3558 | 0.5 |
Loa Loa (eye worm) | jmjC domain-containing protein | 0.0135 | 0.159 | 0.5 |
Echinococcus granulosus | Jumonji AT rich interactive domain 1B | 0.011 | 0.1217 | 1 |
Plasmodium vivax | peptide deformylase, putative | 0.0701 | 1 | 1 |
Mycobacterium leprae | PROBABLE POLYPEPTIDE DEFORMYLASE DEF (PDF) (FORMYLMETHIONINE DEFORMYLASE) | 0.0701 | 1 | 0.5 |
Schistosoma mansoni | jumonji/arid domain-containing protein | 0.0087 | 0.0874 | 0.5 |
Mycobacterium ulcerans | peptide deformylase | 0.0701 | 1 | 0.5 |
Mycobacterium tuberculosis | Probable polypeptide deformylase Def (PDF) (formylmethionine deformylase) | 0.0701 | 1 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.